Video

Sickle cell disease guidelines release set for early 2019


 

FROM ASH 2018

– State-of-the-art guidelines for treating sickle cell disease are actively being developed and could be released as early as the spring of 2019, according to Robert Liem, MD, chair of the American Society of Hematology coordination panel for the initiative.

The new clinical practice recommendations will expand on 2014 guidelines published by the National Heart, Lung, and Blood Institute in a way that will help both hematologists and nonhematologists who take care of patients with sickle cell disease, Dr. Liem said in a video interview at the annual meeting of the American Society of Hematology.

Five different guidelines are under development to cover different aspects of acute and chronic complications of sickle cell disease, including pain, cardiopulmonary and kidney disease, cerebrovascular disease, transfusion support, and stem cell transplantation.


Watch the video to learn more about the guideline effort from the perspective of Dr. Liem, who is also the director of the Comprehensive Sickle Cell Program at the Ann & Robert H. Lurie Children’s Hospital of Chicago.

Recommended Reading

FDA approves hydroxyurea for pediatric patients with sickle cell anemia
MDedge Pediatrics
FDA grants breakthrough therapy designation for severe aplastic anemia drug
MDedge Pediatrics
Children with sickle cell anemia fall short on antibiotic adherence
MDedge Pediatrics
Too few Michigan children with SCD receive pneumococcal, meningococcal vaccines
MDedge Pediatrics
FDA approves long-acting ESA for dialysis-related anemia in children, adolescents
MDedge Pediatrics
Integrated pain program reduced LOS for sickle cell patients
MDedge Pediatrics
Few clinical outcomes convincingly linked to sickle cell trait
MDedge Pediatrics
Researchers seek more sickle cell drug research
MDedge Pediatrics
Daily hydroxyurea effective, safe for African children
MDedge Pediatrics
New treatments promise sickle cell “cure” for all ages
MDedge Pediatrics